Autopsy report · NCT00524030
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures
Cause of deathNo reason given
“See termination reason in detailed description.”
Life of this trial
- Ran for about 3 years 9 months before it stopped.
- 161 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Industry
- Conditions
- Epilepsies, Partial
- Interventions
- pregabalin 600 mg/day; pregabalin 150 mg/day
- Participants
- 161
- Sites
- 73
- Countries
- Czechia, Hong Kong, Ukraine, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.